- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02537392
Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease
Primary Prevention of Multi-micronutrient Supplementation During Peri-conception Against Congenital Heart Disease: A Community-based Randomised Controlled Trial in China
Study Overview
Status
Conditions
Detailed Description
Congenital heart disease (CHD) is among the most prevalent congenital abnormalities with an incidence of about 8-12/1,000 live births, and is also the leading cause of infant morbidity and death from birth defects. A series of studies pointed out that the poor nutritional status of the mother during peri-conception might be the important cause of CHD. In maternal folic acid/ vitamin B deficiency homocysteine accumulates in the serum, and elevated circulating homocysteine concentrations have been associated with the risk of CHD. However, it is still questionable whether multiple vitamin B supplements during peri-conception can reduce CHD risk more effectively compared with the supplement of folic acid alone. Moreover, one randomized controlled trial performed in Shaanxi China confirmed that the supplement of iron and folic acid during pregnancy can significantly reduce early neonatal deaths. It is noteworthy that one-fourth of newborn deaths are attributable to birth defects. Thus, it is worthwhile to investigate whether iron supplement can reduce the risk of CHD.
This community-based randomized controlled trial will assess and compare the impact of daily oral supplements of vitamin B complex along with folic acid or supplements of iron plus folic acid vs. folic acid alone given to women during peri-conception on CHD. It will also assess the effects of the three different supplementations on other pregnancy outcomes and maternal health. The study will be conducted in three rural poor counties including Xunyi, Changwu, and Bin, which are located in Shaanxi Province of Northwest China. All participants will sign informed consent before the study. The investigators hypothesize that the newborn infants of women receiving supplements of vitamin B complex along with folic acid or supplements of iron plus folic acid will experience a reduction in the prevalence of infants with the pulse oxygen saturation less than 95% and other adverse pregnancy outcomes compared with those receiving folic acid alone. The results of this trial will provide evidence needed to formulate policy on maternal micronutrient supplementation during peri-conception and the rationale for the necessary investment of public funds to implement appropriate programs against birth defects.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- Xi'an Jiaotong University College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women of reproductive age (15-49 years) who reside in the study areas;
- Women who are prepared for pregnancy in 1-3 months or have already been pregnant for less than 20 months;
- Women who have provided written informed consent.
Exclusion Criteria:
- Women who have already taken supplements containing vitamin B complex, iron, or folic acid for more than two weeks at enrollment;
- Women who have given birth to children with congenital heart disease or other birth defects before;
- Women with diabetes;
- women with severe heart, liver or kidney disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin B Complex and Folic Acid
Daily supplements containing vitamin B1 (2 mg), vitamin B2 (2 mg), vitamin B6 (2 mg), vitamin B12 (2 μg), calcium pantothenate (2 mg), nicotinamide (15 mg) and folic acid (0.4 mg).
|
Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
|
Experimental: Iron and Folic Acid
Daily supplements of iron (60 mg) and folic acid (0.4 mg).
|
Daily oral dose of 60 mg iron and 0.4 mg folic acid.
|
Active Comparator: Folic Acid
Daily supplement of 0.4 mg folic acid.
|
Daily oral dose of 0.4 mg folic acid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neonatal pulse oximetry oxygen saturation measured by pulse oximetry
Time Frame: 6-72 hours after delivery
|
Neonatal pulse oximetry oxygen saturation (SpO2) is tested by pulse oximetry in babies aged between 6 h and 72 h after birth.
Pulse oximetry testing is repeated 4 h later if the first measurement is between 90% and 95%.
The result of SpO2 will be reported as a dichotomous variable, in which the result is deemed positive if an SpO2 less than 95% is obtained both on the right hand and on either foot on two measures, separated by 4 h; a difference between the two extremities was more than 3% on two measures, separated by 4 h; or any measure is less than 90%.
The result of SpO2 will also be reported as a continuous variable.
|
6-72 hours after delivery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of congenital heart disease and the subtypes
Time Frame: Half a year after delivery
|
Congenital heart disease will be diagnosed by trained clinicians with the help of echocardiography, pulse oximetry, clinical examination, cardiac surgery, or autopsy.
The incidence of congenital heart disease and the subtypes will be reported in each group.
|
Half a year after delivery
|
Incidence of birth defects and the subtypes
Time Frame: Half a year after delivery
|
Birth defects will be diagnosed by trained clinicians.
The incidence of birth defects and the subtypes will be reported in each group.
|
Half a year after delivery
|
Birth weight measured by baby scale
Time Frame: Within 1 hours of delivery
|
Birth weight will be measured within 1 hour of delivery using a baby scale with the precision to the nearest 50 gram.
|
Within 1 hours of delivery
|
Incidence of low birth weight
Time Frame: Within 1 hour of delivery
|
Birth weight will be measured within 1 hour of delivery using a baby scale.
The incidence of low birth weight will be reported in each group based on the criteria of birth weight less than 2500 gram.
|
Within 1 hour of delivery
|
Gestational age at birth
Time Frame: At delivery
|
Gestational age at birth will be measured as completed days based on the last menstrual period.
|
At delivery
|
Incidence of preterm birth
Time Frame: At delivery
|
Gestational age at birth will be measured as completed days based on the last menstrual period.
The incidence of preterm birth (infant born less than 37 weeks gestational age) will be reported in each group.
|
At delivery
|
Incidence of perinatal mortality
Time Frame: Between 28 weeks of gestational duration and 7 days after delivery
|
The incidence of perinatal mortality (Infants death between 28 weeks of gestational duration and 7 days after delivery) will be reported in each group.
|
Between 28 weeks of gestational duration and 7 days after delivery
|
Incidence of stillbirth
Time Frame: At delivery
|
The incidence of stillbirth (infants death at delivery) will be reported in each group.
|
At delivery
|
Incidence of neonatal mortality
Time Frame: First 28 days after birth
|
The incidence of neonatal mortality (infants death during the first 28 days after birth) will be reported in each group.
|
First 28 days after birth
|
Incidence of early neonatal mortality
Time Frame: First 7 days after birth
|
The incidence of early neonatal mortality (infants death during the first 7 days after birth) will be reported in each group.
|
First 7 days after birth
|
Incidence of pregnancy complications: hypertension, preeclampsia, antepartum haemorrhage, and infections
Time Frame: After enrollment until at delivery
|
Pregnancy complications (hypertension, preeclampsia, antepartum haemorrhage, and infections) will be diagnosed by trained clinicians during antenatal care checks.
All information will be recorded in the pregnant women's medical records of antenatal care checks and delivery.
The incidence of hypertension, preeclampsia, antepartum haemorrhage, and infections among participants will be reported in each group.
|
After enrollment until at delivery
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hong Yan, Professor, Health Science Center of Xi'an Jiaotong University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NSFC81230016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Disease
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Disease CongenitalUnited States
-
Vanderbilt University Medical CenterEnrolling by invitationCongenital Heart Disease | Congenital Heart Defect | Congenital Heart MalformationsUnited States
-
YHAlattarNot yet recruitingCritical Congenital Heart Disease
-
University Hospital TuebingenCompletedComplex Congenital Heart DiseaseGermany
-
The Hospital for Sick ChildrenCompletedCongenital Heart Disease (CHD)Canada
-
University College, LondonSociety for Cardiothoracic Surgery in Great Britain & Ireland; British Congenital...Unknown
-
University of California, DavisCompletedCyanotic Congenital Heart DiseaseUnited States
-
Assistance Publique Hopitaux De MarseilleRecruitingComplex Congenital Heart DiseaseFrance
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's HospitalEnrolling by invitation
Clinical Trials on Vitamin B Complex and Folic Acid
-
National Taiwan University HospitalUnknownAtrophic Glossitis, Burning Mouth SyndromeTaiwan
-
Mundipharma (China) Pharmaceutical Co. LtdCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed T-Cell LymphomaChina
-
Medical University of GrazCompletedHealthy | Oxidative Stress | Vitamin B 12 Deficiency | Polyphenols | Thiamine and Niacin Deficiency States | Pyridoxine Deficiency | Folic Acid Deficiency Anemia, Dietary | Peroxidase; Defect | Homocystine; Metabolic DisorderAustria
-
Fondazione Policlinico Universitario Agostino Gemelli...CompletedIron-deficiency | Anemia | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Blood Loss Anemia | Erythropoiesis AbnormalItaly
-
University of GeorgiaEmory University; University of FloridaCompleted
-
Fundacion para la Investigacion Biomedica del Hospital...Completed
-
University of CalgaryNot yet recruitingExtreme Prematurity | Anemia of PrematurityCanada
-
Azienda Ospedaliera Universitaria Integrata VeronaInternational Centre of Birth DefectsUnknown
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedHealthy | Pharmacokinetics
-
Ludwig-Maximilians - University of MunichEuropean UnionCompleted